Advertisement
Advertisement
U.S. markets close in 3 hours 15 minutes
Advertisement
Advertisement
Advertisement
Advertisement

SIGA Technologies, Inc. (SIGA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
23.57+1.38 (+6.22%)
As of 12:45PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close22.19
Open22.20
Bid23.65 x 1100
Ask23.69 x 1100
Day's Range21.92 - 24.42
52 Week Range5.84 - 24.42
Volume11,925,872
Avg. Volume16,599,379
Market Cap1.721B
Beta (5Y Monthly)0.63
PE Ratio (TTM)21.43
EPS (TTM)1.10
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMay 16, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-10% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for SIGA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • SIGA Technologies Inc.
    Analyst Report: Emergent BioSolutions IncEmergent BioSolutions makes vaccines and other products intended to protect civilian and military populations from emerging infectious diseases and chemical, biological or nuclear attacks. The company generates its revenue from product sales of its smallpox vaccine (ACAM2000), its anthrax vaccines (BioThrax and AV7909), and its Narcan nasal spray (a treatment for opioid overdoses), as well as from contract development and manufacturing services and contracts and grants. The USG is the company's primary customer, and provides EBS with significant product development funding. EBS shares are a component of the S&P 400 Index. The company has approximately 2,400 employees.
    Rating
    Fair Value
    Economic Moat
    22 days agoArgus Research
View more
Advertisement
Advertisement